Please select a video from the list below.
New Therapies for Group 1 PAH
In this program, Drs. Vallerie McLaughlin, Ioana Preston and Rajan Saggar consider important findings from recent analyses from the landmark GRIPHON and SERAPHIN trials of selexipag and macitentan. The Phase 2 trial of the emerging IP receptor agonist ralinepag is discussed and the impact of PAH therapies on the quality of life of patients is reviewed in light of the TRACE study that examines patient perceptions of “well being”.
Recent Video
| 
Most Viewed
Specialties :                    Search :
RESPITE Study Results
RESPITE Study Results Views - 1311
ICU Management of PH
ICU Management of PH Views - 178